Objective To compare the effect of riluzole on median survival in population studies of
patients with amyotrophic lateral sclerosis (ALS) with that observed in clinical trials …

Neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease,
Huntington's disease and amyotrophic lateral sclerosis, are a group of incurable …

Background In a phase 2 study, dexpramipexole (25–150 mg twice daily) was well tolerated
for up to 9 months and showed a significant benefit at the high dose in a combined …

Amyotrophic lateral sclerosis (ALS) is a fatal neurological disease characterized by the
degeneration of motor neurons. Currently, there is no effective therapy for ALS. Stem cell …

Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive neurodegenerative disease
characterized by the loss of motor neurons in the motor cortex, brain stem and spinal cord …

Importance The prognostic value of slow vital capacity (SVC) in relation to respiratory
function decline and disease progression in patients with amyotrophic lateral sclerosis (ALS) …

Introduction: Spinal cord disorders (SCDs) are among the most devastating neurological
diseases, due to their acute and long-term health consequences, the reduced quality of life …

There is a desperate need for targeted therapeutic interventions that slow the progression of
amyotrophic lateral sclerosis (ALS). ALS is a disorder with heterogeneous onset, which then …

Stem cells (SCs) are clonogenic cells that develop into the specialized cells which later
responsible for making up various types of tissue in the human body. SCs are not only the …

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting the
neuromuscular system and does not have a known singular cause. Genetic mutations …